FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3155252008> ?p ?o ?g. }

• W3155252008 endingPage "e1498" @default.
• W3155252008 startingPage "731" @default.
• W3155252008 abstract "Abstract Lessons Learned This study suggests that trametinib has significant clinical activity in non-V600 BRAF mutation and BRAF fusion metastatic melanoma, albeit in a small cohort. All patients with metastatic melanoma should undergo sequencing of the BRAF gene to identify noncanonical BRAF mutations that may indicate benefit from treatment with trametinib. Background Non-V600 BRAF mutations and BRAF fusions in aggregate occur in approximately 5% of all melanomas. Inhibition of the mitogen-activated protein kinase (MAPK) pathway has been implicated as a possible treatment strategy for these patients. Methods In this open-label, multicenter, phase II study, patients with advanced melanoma harboring mutations in BRAF outside V600 (non-V600) or BRAF fusions received trametinib 2.0 mg daily. Patients were divided into cohorts based on the intrinsic catalytic activity of BRAF mutation (high, cohort A; low/unknown, cohort B). The primary endpoint was objective response rate (ORR) for patients in cohort A; secondary endpoints included ORR in cohort B, safety, and survival in both treatment arms. Results Among all patients, the ORR was 33% (three of nine patients), including 67% in cohort A and 17% in cohort B. Two patients had stable disease as best response, and six patients had some degree of tumor shrinkage. The median progression-free survival (PFS) was 7.3 months. Treatment-related adverse events occurred in all patients (100%); most (89%) were grade 1–2. Conclusion In contrast to recently described tumor-agnostic studies in a genetically similar population, trametinib had considerable activity in a small population of patients with melanoma harboring BRAF non-V600 mutations and fusions, providing rationale for sequencing in search of these genomic alterations." @default.
• W3155252008 created "2021-04-26" @default.
• W3155252008 creator A5008479799 @default.
• W3155252008 creator A5014348600 @default.
• W3155252008 creator A5023174631 @default.
• W3155252008 creator A5025067315 @default.
• W3155252008 creator A5037844360 @default.
• W3155252008 creator A5048327749 @default.
• W3155252008 creator A5075566772 @default.
• W3155252008 date "2021-05-04" @default.
• W3155252008 modified "2023-09-27" @default.
• W3155252008 title "Efficacy and Safety of Trametinib in <scp>Non-V600 <i>BRAF</i> </scp> Mutant Melanoma: A Phase II Study" @default.
• W3155252008 cites W1441792155 @default.
• W3155252008 cites W1764134105 @default.
• W3155252008 cites W1917720781 @default.
• W3155252008 cites W1918248652 @default.
• W3155252008 cites W2053343049 @default.
• W3155252008 cites W2124662474 @default.
• W3155252008 cites W2128327828 @default.
• W3155252008 cites W2146772089 @default.
• W3155252008 cites W2163188200 @default.
• W3155252008 cites W2409383155 @default.
• W3155252008 cites W2491982852 @default.
• W3155252008 cites W2526607882 @default.
• W3155252008 cites W2560709471 @default.
• W3155252008 cites W2605233023 @default.
• W3155252008 cites W2613362156 @default.
• W3155252008 cites W2761314488 @default.
• W3155252008 cites W2766581537 @default.
• W3155252008 cites W2808608845 @default.
• W3155252008 cites W2894448865 @default.
• W3155252008 cites W2977293565 @default.
• W3155252008 cites W2980620763 @default.
• W3155252008 cites W2998901450 @default.
• W3155252008 doi "https://doi.org/10.1002/onco.13795" @default.
• W3155252008 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8417872" @default.
• W3155252008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33861486" @default.
• W3155252008 hasPublicationYear "2021" @default.
• W3155252008 type Work @default.
• W3155252008 sameAs 3155252008 @default.
• W3155252008 citedByCount "16" @default.
• W3155252008 countsByYear W31552520082022 @default.
• W3155252008 countsByYear W31552520082023 @default.
• W3155252008 crossrefType "journal-article" @default.
• W3155252008 hasAuthorship W3155252008A5008479799 @default.
• W3155252008 hasAuthorship W3155252008A5014348600 @default.
• W3155252008 hasAuthorship W3155252008A5023174631 @default.
• W3155252008 hasAuthorship W3155252008A5025067315 @default.
• W3155252008 hasAuthorship W3155252008A5037844360 @default.
• W3155252008 hasAuthorship W3155252008A5048327749 @default.
• W3155252008 hasAuthorship W3155252008A5075566772 @default.
• W3155252008 hasBestOaLocation W31552520081 @default.
• W3155252008 hasConcept C104317684 @default.
• W3155252008 hasConcept C126322002 @default.
• W3155252008 hasConcept C143998085 @default.
• W3155252008 hasConcept C184235292 @default.
• W3155252008 hasConcept C188816634 @default.
• W3155252008 hasConcept C197934379 @default.
• W3155252008 hasConcept C203092338 @default.
• W3155252008 hasConcept C2776131300 @default.
• W3155252008 hasConcept C2777658100 @default.
• W3155252008 hasConcept C2778472372 @default.
• W3155252008 hasConcept C2778830669 @default.
• W3155252008 hasConcept C2781249067 @default.
• W3155252008 hasConcept C2908647359 @default.
• W3155252008 hasConcept C2994587330 @default.
• W3155252008 hasConcept C501734568 @default.
• W3155252008 hasConcept C502942594 @default.
• W3155252008 hasConcept C535046627 @default.
• W3155252008 hasConcept C54355233 @default.
• W3155252008 hasConcept C57074206 @default.
• W3155252008 hasConcept C71924100 @default.
• W3155252008 hasConcept C72563966 @default.
• W3155252008 hasConcept C86803240 @default.
• W3155252008 hasConcept C99454951 @default.
• W3155252008 hasConceptScore W3155252008C104317684 @default.
• W3155252008 hasConceptScore W3155252008C126322002 @default.
• W3155252008 hasConceptScore W3155252008C143998085 @default.
• W3155252008 hasConceptScore W3155252008C184235292 @default.
• W3155252008 hasConceptScore W3155252008C188816634 @default.
• W3155252008 hasConceptScore W3155252008C197934379 @default.
• W3155252008 hasConceptScore W3155252008C203092338 @default.
• W3155252008 hasConceptScore W3155252008C2776131300 @default.
• W3155252008 hasConceptScore W3155252008C2777658100 @default.
• W3155252008 hasConceptScore W3155252008C2778472372 @default.
• W3155252008 hasConceptScore W3155252008C2778830669 @default.
• W3155252008 hasConceptScore W3155252008C2781249067 @default.
• W3155252008 hasConceptScore W3155252008C2908647359 @default.
• W3155252008 hasConceptScore W3155252008C2994587330 @default.
• W3155252008 hasConceptScore W3155252008C501734568 @default.
• W3155252008 hasConceptScore W3155252008C502942594 @default.
• W3155252008 hasConceptScore W3155252008C535046627 @default.
• W3155252008 hasConceptScore W3155252008C54355233 @default.
• W3155252008 hasConceptScore W3155252008C57074206 @default.
• W3155252008 hasConceptScore W3155252008C71924100 @default.
• W3155252008 hasConceptScore W3155252008C72563966 @default.
• W3155252008 hasConceptScore W3155252008C86803240 @default.
• W3155252008 hasConceptScore W3155252008C99454951 @default.

• next